VistaGen Therapeutics (VTGN) to Release Earnings on Tuesday

VistaGen Therapeutics (NASDAQ:VTGN) is expected to be posting its Q4 2026 results after the market closes on Tuesday, June 16th. Analysts expect the company to announce earnings of ($0.3367) per share and revenue of $0.40 million for the quarter. Individuals can check the company’s upcoming Q4 2026 earning summary page for the latest details on the call scheduled for Thursday, June 18, 2026 at 4:00 PM ET.

VistaGen Therapeutics Stock Performance

VistaGen Therapeutics stock opened at $0.54 on Tuesday. VistaGen Therapeutics has a fifty-two week low of $0.43 and a fifty-two week high of $5.14. The company has a market capitalization of $21.28 million, a price-to-earnings ratio of -0.28 and a beta of 0.31. The stock has a fifty day moving average of $0.60 and a two-hundred day moving average of $1.15.

Analysts Set New Price Targets

VTGN has been the topic of a number of analyst reports. Wall Street Zen lowered VistaGen Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Weiss Ratings reissued a “sell (e+)” rating on shares of VistaGen Therapeutics in a research note on Wednesday, June 3rd. Four analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Reduce” and an average target price of $0.95.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of VTGN. Bank of America Corp DE boosted its holdings in shares of VistaGen Therapeutics by 1,068.0% during the fourth quarter. Bank of America Corp DE now owns 21,141 shares of the company’s stock worth $62,000 after purchasing an additional 19,331 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new stake in shares of VistaGen Therapeutics in the first quarter valued at $25,000. Marshall Wace LLP purchased a new stake in shares of VistaGen Therapeutics in the second quarter valued at $69,000. Jane Street Group LLC purchased a new stake in shares of VistaGen Therapeutics in the second quarter valued at $190,000. Finally, Dimensional Fund Advisors LP grew its position in shares of VistaGen Therapeutics by 56.9% in the third quarter. Dimensional Fund Advisors LP now owns 68,017 shares of the company’s stock valued at $241,000 after purchasing an additional 24,655 shares during the period. 78.39% of the stock is currently owned by institutional investors and hedge funds.

About VistaGen Therapeutics

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.